share_log

Johnson & Johnson | 424B2: Prospectus

Johnson & Johnson | 424B2: Prospectus

強生 | 424B2：募資說明書
美股sec公告 ·  05/15 16:36
Moomoo AI 已提取核心訊息
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes totaling $4 billion, with varying maturities and interest rates. The notes, due in 2029, 2031, 2034, and 2054, will pay interest semi-annually beginning December 1, 2024. The offering includes $1,150,000,000 of 4.800% notes due 2029, $1,150,000,000 of 4.900% notes due 2031, $850,000,000 of 4.950% notes due 2034, and $850,000,000 of 5.250% notes due 2054. The notes are senior unsecured obligations and will rank equally with other unsecured and unsubordinated debt. The company may redeem the notes at any time at specified redemption prices. The proceeds are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The notes will be delivered through The Depository Trust Company on May 20, 2024, with J.P. Morgan, BofA Securities, and Citigroup acting as Joint Book-Running Managers.
Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the issuance of a series of senior unsecured notes totaling $4 billion, with varying maturities and interest rates. The notes, due in 2029, 2031, 2034, and 2054, will pay interest semi-annually beginning December 1, 2024. The offering includes $1,150,000,000 of 4.800% notes due 2029, $1,150,000,000 of 4.900% notes due 2031, $850,000,000 of 4.950% notes due 2034, and $850,000,000 of 5.250% notes due 2054. The notes are senior unsecured obligations and will rank equally with other unsecured and unsubordinated debt. The company may redeem the notes at any time at specified redemption prices. The proceeds are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The notes will be delivered through The Depository Trust Company on May 20, 2024, with J.P. Morgan, BofA Securities, and Citigroup acting as Joint Book-Running Managers.
領先的醫療保健公司強生公司（JNJ.US）宣佈發行一系列總額爲40億美元的優先無抵押票據，期限和利率各不相同。這些票據將於2029年、2031年、2034年和2054年到期，將從2024年12月1日起每半年支付利息。此次發行包括2029年到期的1.15億美元4.800％票據、1.15億美元2031年到期的4.900％票據、2034年到期的8.5億美元4.950％票據以及2054年到期的8.5億美元5.250％票據。這些票據是優先無抵押債務，將與其他無抵押和非次級債務同等排名。公司可以隨時以指定的贖回價格兌換票據。所得款項將用於一般公司用途，包括最近宣佈的對Shockwave Medical, Inc. 的收購，但須遵守慣例成交條件和監管部門的批准。這些票據將於2024年5月20日通過存託信託公司交付，摩根大通、美銀證券和花旗集團將擔任聯席賬面管理人。
領先的醫療保健公司強生公司（JNJ.US）宣佈發行一系列總額爲40億美元的優先無抵押票據，期限和利率各不相同。這些票據將於2029年、2031年、2034年和2054年到期，將從2024年12月1日起每半年支付利息。此次發行包括2029年到期的1.15億美元4.800％票據、1.15億美元2031年到期的4.900％票據、2034年到期的8.5億美元4.950％票據以及2054年到期的8.5億美元5.250％票據。這些票據是優先無抵押債務，將與其他無抵押和非次級債務同等排名。公司可以隨時以指定的贖回價格兌換票據。所得款項將用於一般公司用途，包括最近宣佈的對Shockwave Medical, Inc. 的收購，但須遵守慣例成交條件和監管部門的批准。這些票據將於2024年5月20日通過存託信託公司交付，摩根大通、美銀證券和花旗集團將擔任聯席賬面管理人。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息